Chapter 8
BCG Adverse Effects & Management
Grading of local and systemic adverse events, BCGitis management algorithms, treatment protocols for severe complications, and evidence-based criteria for BCG discontinuation.
Overview of BCG Toxicity
Local AE Rate
62.8%
Systemic AE Rate
30.6%
Discontinuation
7.8%
BCG Sepsis
0.3%
Intravesical BCG is the most effective prophylactic treatment for high-risk NMIBC, but its immunological mechanism of action inevitably produces adverse events. The largest contemporary dataset (EORTC 30962, n=1,316) reported that 62.8% of patients experienced local side effects and 30.6% had systemic symptoms. Approximately 7.8% discontinued treatment due to toxicity, with most discontinuations occurring during the first year. Importantly, the frequency of adverse events was similar during induction, the first year of maintenance, and subsequent years — suggesting that host factors rather than cumulative exposure determine toxicity.
BCG-related adverse events can be broadly classified into local reactions (cystitis, haematuria, frequency) and systemic reactions (fever, malaise, and rarely sepsis or disseminated BCGosis). The pathogenesis involves both direct bacterial infection and immune-mediated hypersensitivity. Severe complications can occur at any instillation — even the first — and may present weeks to years after treatment completion, making early recognition and patient education critical.
Local Adverse Events — Grading & Management
Local adverse events are the most common complications of intravesical BCG, affecting approximately two-thirds of patients. These include BCG-induced cystitis (35%), bacterial urinary tract infection (23.3%), urinary frequency >1/hour (23.6%), and macroscopic haematuria (22.6%). Most local symptoms are self-limiting within 48–72 hours and can be managed conservatively.
| Grade | Symptoms | Duration | Management | BCG Decision |
|---|---|---|---|---|
| Grade 1 (Mild) | Mild dysuria, frequency, urgency; microscopic haematuria | < 48 h | Reassurance; phenazopyridine; increased fluid intake; anticholinergics PRN | Continue BCG |
| Grade 2 (Moderate) | Moderate cystitis; gross haematuria; frequency >1/h; pain requiring analgesics | 48–72 h | NSAIDs; oxybutynin/mirabegron; urine culture to r/o UTI; consider dose reduction (1/3 dose) | Delay 1–2 weeks; consider dose reduction |
| Grade 3 (Severe) | Severe cystitis >72h; bladder contracture symptoms; persistent gross haematuria requiring intervention | > 72 h | Fluoroquinolone (empiric); INH 300mg × 3 months if BCG cystitis suspected; cystoscopy if haematuria persists | Hold BCG; reassess after resolution |
| Grade 4 (Life-threatening) | Bladder contracture requiring diversion; ureteral obstruction; renal failure | Persistent | Urgent urological intervention; triple anti-TB therapy; consider cystectomy | Permanently discontinue BCG |
Specific Local Complications
| Complication | Incidence | Presentation | Management |
|---|---|---|---|
| Granulomatous prostatitis | 0.9–1.3% | Perineal pain, elevated PSA, hard prostate on DRE | INH + rifampicin × 3–6 months; fluoroquinolone |
| Epididymo-orchitis | 0.2–0.4% | Scrotal pain/swelling; may be bilateral | Triple anti-TB × 3–6 months; orchiectomy if abscess |
| Contracted bladder | < 0.5% | Progressive frequency, reduced capacity (<150 mL) | Anti-TB therapy; augmentation cystoplasty or cystectomy |
| Ureteral obstruction | < 0.3% | Hydronephrosis, flank pain, elevated creatinine | Ureteral stent; anti-TB therapy; nephrectomy if non-functional |
Systemic Adverse Events — Grading & Management
Systemic adverse events range from common self-limiting symptoms (malaise, low-grade fever) to rare but potentially fatal complications (BCG sepsis, disseminated BCGosis). The distinction between immune-mediated reactions and true mycobacterial infection is clinically critical, as it determines the treatment approach. Fever >38.5°C persisting >48 hours after instillation should be considered a red flag requiring urgent evaluation.
| Grade | Symptoms | Duration | Management | BCG Decision |
|---|---|---|---|---|
| Grade 1 (Mild) | Malaise, low-grade fever (<38.5°C), myalgia, flu-like symptoms | < 48 h | Paracetamol/NSAIDs; rest; hydration | Continue BCG |
| Grade 2 (Moderate) | Fever 38.5–39.5°C; moderate malaise affecting daily activities; arthralgia | 48–72 h | Antipyretics; fluoroquinolone empirically; blood cultures; monitor | Delay BCG; reassess |
| Grade 3 (Severe) | High fever >39.5°C persisting >72h; pneumonitis; hepatitis; reactive arthritis; skin rash/erythema nodosum | > 72 h | Hospitalization; INH + rifampicin + ethambutol; corticosteroids for immune-mediated reactions; organ-specific workup | Hold BCG; likely permanent discontinuation |
| Grade 4 (BCG Sepsis) | Septic shock; DIC; multi-organ failure; disseminated BCGosis (miliary pattern on CXR) | Acute onset | ICU admission; triple anti-TB (INH + RIF + EMB) × 6–12 months; high-dose corticosteroids (prednisolone 40mg); supportive care | Permanently discontinue BCG |
"Severe complications are treated with three or four tuberculostatics over 3–12 months, depending on the severity. Corticosteroids are an essential therapy in BCG septicemia. NSAIDs and corticosteroids can efficiently manage immunological complications."
— Decaestecker K & Oosterlinck W, Res Rep Urol 2015
BCGitis — Recognition & Management Algorithm
"BCGitis" is a collective term encompassing the spectrum of BCG-related inflammatory and infectious complications beyond simple cystitis. It includes granulomatous inflammation of any organ system triggered by BCG instillation. The distinction between immune-mediated BCGitis (sterile granulomatous inflammation) and true BCG infection (viable organisms in tissue) is critical for treatment decisions.
Step-by-Step Management Algorithm
Initial Assessment (Within 24–48h post-instillation)
Document symptom onset, severity, and duration. Perform urinalysis and urine culture. Check temperature, vital signs, and basic labs (CBC, CRP, LFTs, creatinine). If fever >38.5°C persists >48h → proceed to Step 2.
Rule Out Bacterial UTI
If urine culture positive for conventional bacteria → treat UTI; BCG can resume after resolution. If urine culture negative and symptoms persist → suspect BCGitis; proceed to Step 3.
Classify BCGitis Type
Local BCGitis: Symptoms confined to lower urinary tract (cystitis, prostatitis). Systemic BCGitis: Fever, pneumonitis, hepatitis, arthritis, skin manifestations. Disseminated BCGosis: Multi-organ involvement, septic picture, miliary pattern.
Initiate Treatment Based on Classification
Local BCGitis → Fluoroquinolone ± INH 300mg/day × 3 months. Systemic immune-mediated → Corticosteroids (prednisolone 20–40mg) + INH + RIF × 3 months. Disseminated BCGosis/Sepsis → ICU; triple anti-TB (INH + RIF + EMB) × 6–12 months + high-dose steroids.
Follow-up & BCG Resumption Decision
After resolution: Grade 1–2 local → may resume BCG at reduced dose (1/3 dose) after 2-week delay. Grade 3 local or any systemic → individualized decision; consider alternative intravesical therapy. Grade 4 or disseminated → permanently discontinue BCG; consider radical cystectomy or novel agents.
Diagnostic Workup for Suspected BCGitis
| Investigation | Purpose | Sensitivity | Notes |
|---|---|---|---|
| AFB stain (urine/tissue) | Detect acid-fast bacilli | Low (25–30%) | Often negative; does not exclude BCGitis |
| Mycobacterial culture | Confirm viable BCG organisms | Low–Moderate | Requires 6–8 weeks; special media (Löwenstein-Jensen) |
| PCR for M. bovis BCG | Rapid molecular detection | Moderate–High (70–80%) | Faster than culture; may be negative in immune-mediated BCGitis |
| Tissue biopsy (granulomas) | Histological confirmation | High for granulomas | Non-caseating granulomas suggest BCGitis; caseating suggests active infection |
| CT chest/abdomen | Evaluate dissemination | High for miliary | Miliary pattern, hepatosplenic granulomas, lymphadenopathy |
When to Hold, Reduce, or Discontinue BCG
The decision to modify or discontinue BCG therapy requires balancing the oncological risk of undertreating high-risk NMIBC against the morbidity of continued BCG exposure. The IBCG (International Bladder Cancer Group) and EAU guidelines provide a framework for these decisions. Importantly, BCG intolerance — defined as inability to complete adequate BCG due to toxicity — does not constitute BCG-unresponsive disease and patients may still benefit from alternative intravesical approaches.
CONTINUE BCG
- • Grade 1 local symptoms <48h
- • Low-grade fever <38.5°C resolving within 24h
- • Mild myalgia/malaise <48h
- • Microscopic haematuria only
HOLD / REDUCE DOSE
- • Grade 2 cystitis persisting 48–72h
- • Fever 38.5–39.5°C resolving with antipyretics
- • Gross haematuria (non-clot-forming)
- • Recurrent Grade 1 symptoms at each instillation
- • Consider 1/3 dose BCG at next instillation
DISCONTINUE BCG
- • BCG sepsis or disseminated BCGosis
- • Fever >39.5°C persisting >72h
- • Granulomatous hepatitis or pneumonitis
- • Symptomatic contracted bladder
- • Grade 3–4 adverse events
- • Persistent Grade 2 despite dose reduction
"Approximately 70% of patients receiving BCG complain of side effects with 8% of these being severe enough to discontinue treatment. BCG intolerance does not equal BCG-unresponsive disease — these patients may still benefit from alternative intravesical therapies."
— AUA/SUO Guidelines on NMIBC, 2024
Anti-Tuberculosis Treatment Protocols
When BCGitis requires anti-tuberculosis therapy, the choice of regimen and duration depends on the severity and extent of disease. BCG (M. bovis) is intrinsically resistant to pyrazinamide, so standard TB regimens must be modified. The following protocols are based on IBCG recommendations and published expert consensus.
| Indication | Regimen | Duration | Key Notes |
|---|---|---|---|
| Persistent local BCGitis (Grade 3 cystitis) | INH 300mg/day + Rifampicin 600mg/day | 3 months | Add fluoroquinolone for first 2 weeks; monitor LFTs monthly |
| Granulomatous prostatitis / epididymitis | INH + Rifampicin + Ethambutol | 3–6 months | Ethambutol 15mg/kg/day; check visual acuity baseline |
| Systemic BCGitis (pneumonitis, hepatitis, arthritis) | INH + Rifampicin + Ethambutol + Corticosteroids | 6 months | Prednisolone 20–40mg tapered over 4–8 weeks; organ-specific monitoring |
| BCG sepsis / Disseminated BCGosis | INH + Rifampicin + Ethambutol + High-dose steroids | 9–12 months | ICU management; prednisolone 40mg or IV methylprednisolone; DO NOT use pyrazinamide (intrinsic resistance) |
⚠️ Critical Reminder
M. bovis BCG is intrinsically resistant to pyrazinamide. Do NOT include pyrazinamide in anti-TB regimens for BCG-related complications. Standard 4-drug TB regimens (RIPE) must be modified to exclude pyrazinamide.
Prevention & Risk Reduction Strategies
Several strategies have been proposed to reduce BCG toxicity. However, evidence from randomized trials has challenged some previously advocated approaches. The EORTC 30962 trial demonstrated that one-third dose BCG did not significantly reduce toxicity compared to full dose, and prophylactic ofloxacin or oxybutynin were not confirmed effective in subsequent RCTs.
| Strategy | Evidence Level | Recommendation | Comments |
|---|---|---|---|
| Avoid traumatic catheterization | Expert consensus | Strongly recommended | Postpone if traumatic catheterization; risk of systemic absorption |
| Wait ≥2 weeks post-TURBT | Expert consensus | Strongly recommended | Allow mucosal healing; reduces systemic absorption risk |
| Treat active UTI before BCG | Expert consensus | Strongly recommended | Inflamed urothelium increases BCG absorption |
| Reduce dwell time to 1 hour | Level 3 | Consider in recurrent AEs | Standard is 2h; reducing to 1h may decrease local toxicity |
| 1/3 dose BCG | Level 1b (EORTC 30962) | Not proven to reduce toxicity | May reduce efficacy in high-risk; toxicity similar to full dose |
| Prophylactic ofloxacin | Level 1b | Not recommended | RCTs failed to confirm benefit; may reduce BCG efficacy |
| Prophylactic oxybutynin | Level 1b | Not recommended | RCT showed no benefit over placebo for BCG-related LUTS |
Patient Education & Communication
Patient education is considered the single most important strategy for managing BCG adverse events. Anticipatory guidance regarding expected symptoms, their duration, and alarm signs significantly reduces anxiety, emergency department visits, and premature treatment discontinuation. Both the patient and their primary care physician should receive written information about BCG therapy and its potential complications.
BCG Intravesical Therapy — Patient Information Card
Please keep this card for reference after each BCG treatment session.
✓ Expected Symptoms (Normal)
- • Burning/frequency for 24–48 hours
- • Pink-tinged urine for 24 hours
- • Low-grade fever (<38.5°C) for <24 hours
- • Mild fatigue for 1–2 days
- • Flu-like symptoms for <48 hours
⚠ Red Flags — Seek Immediate Care
- • Fever >38.5°C lasting >48 hours
- • Shaking chills or rigors
- • Gross haematuria with clots >48 hours
- • Severe flank or abdominal pain
- • Joint swelling or skin rash
- • Shortness of breath or persistent cough
- • Jaundice (yellowing of skin/eyes)
"An essential step in the management of complications arising from BCG is written information for both the family doctor and the patient on the possible adverse events and their management. Counseling patients prior to intravesical therapy and providing anticipatory guidance will improve the overall experience and help with earlier recognition of adverse events."
— Koch GE et al., Urology 2020; Decaestecker & Oosterlinck, Res Rep Urol 2015
Key References
- Decaestecker K, Oosterlinck W. Managing the adverse events of intravesical BCG therapy. Res Rep Urol. 2015;7:157–163.
- Brausi M, et al. Side effects of BCG in the treatment of NMIBC: EORTC GU Group study 30962. Eur Urol. 2014;65(1):69–76.
- Koch GE, Smelser WW, Chang SS. Side effects of intravesical BCG and chemotherapy for bladder cancer. Urology. 2021;149:11–20.
- Witjes JA, et al. Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events. Eur Urol Suppl. 2008;7(10):667–674.
- Di Gianfrancesco L, et al. How to reduce BCG discontinuation in patients with severe functional impairment. Curr Urol. 2022;16(3):160–167.
- Green DB, et al. Complications of Intravesical BCG Immunotherapy. RadioGraphics. 2019;39(4):1051–1059.
- AUA/SUO Guideline on Non-Muscle Invasive Bladder Cancer. 2024 Amendment.
- EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). 2024 Update.